A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

Cancer

Volumn 78, Issue 2, 1996, Pages 244-251

  Ratto, Giovanni B ^a   Zino, Paolo ^b   Mirabelli, Sandro ^c   Minuti, Paolo ^b   Aquilina, Riccardo ^c   Fantino, Giovanni ^a   Spessa, Elisabetta ^a   Ponte, Marco ^a   Bruzzi, Paolo ^a   Melioli, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SANTA CORONA HOSPITAL   (Italy)

^c Ospedale Costa Rainera   (Italy)

Author keywords

immunotherapy; interleukin 2; lung carcinoma; surgery; tumor infiltrating lymphocyte

Indexed keywords

CISPLATIN; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PNEUMONECTOMY; POSTOPERATIVE CARE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 8044255270     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L     Document Type: Article

References (23)

1. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminar report. N Engl J Med 1988;319:1676-80.
2. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinatt SM, Pinto CE, et al. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;18:577-80.
3. Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, et al. Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991;68:1-8.
4. Aoki Y, Takakuwa K, Kodama S, Tanuka K, Takahashi H, Tokunaga A, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epitelial ovarian cancer. Cancer Res 1991;51:1934-9.
5. Ravaud A, Legrand E, Delaunay MM, Bussieres E, Coulon V, Cany L, et al. A phase I trial of repeated tumor infiltrating lymphocyte (TIL) infusions in metastatic melanoma. Br J Cancer 1995;71:331-6.
6. Goedegebuure PF, Douville LM, Li O, Richmond GC, Schoof D, Scavone M, et al. Adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 1995;13,8:1939-49.
7. Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin-2 and lymphokine-activated-killer cells after non curative resection of primary lung cancer. Lung Cancer 1995;13:31-44.
8. Melioli G, Ratto GB, Guastella M, Meta M, Biassoni R, Semino C, et al. Isolation and "in vitro" expansion of lymphocytes infiltrating non small cell lung carcinoma: functional and molecular characterization for their use in adoptive immunotherapy. Eur J Cancer 1994;30 A, 1:97-102.
9. Ratto GB, Melioli G, Zino P, Mereu C, Mirabelli S, Fantino G, et al. Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III Non-Small-Cell-Lung-Cancer: a pilot study. J Thorac Cardiovasc Surg 1995;109:1212-7.
10. Mountain CF. A new international staging system for lung cancer. Chest 1986;89:225S-233S.
11. Ratto GB, Piacenza G, Frola C, Musante F, Serrano J, Giua R, et al. Chest wall involvement by lung cancer: computed tomographic detection and results of operation. Ann Thor Surg 1991;51:182-8.
12. Moretta A, Pantaleo G, Moretta L, Cerottini JC, Mingari MC. Direct demonstration of clonogenic potential of every human peripheral blood cell. Clonal analysis of HLA-DR expression and cytolytic activities. J Exp Med 1983;157:743-50.
13. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K. Extended continuous infusion low-dose recombinant IL-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 1991;9,12: 2110-9.
14. Rosemberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with Tumor-Infiltrating Lymphocytes. Science 1986;233:1318-21.
15. Ortaldo JR, Wiltrout RH. Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer. J Natl Cancer Inst 1990;82: 1663-5.
16. Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T, Yagita M. Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 1990;82:1697-701.
17. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell-lung cancer. N Engl J Med 1990;323:940-5.
18. Kreisman H, Lisbona A, Olson L, Propert KJ, Modeas C, Dillman RO, et al. Effect of radiologie stage III substage on nonsurgical therapy of non-small cell lung cancer. Cancer 1993;72:1588-96.
19. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87,3:198-205.
20. Rosell R, Gòmez-Codina J, Camps C, Maestre J, Padille J, Cantò A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
21. Cameron RB, Spiess PJ, Rosemberg SA. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2, and local tumor irradiation. J Exp Med 1990;171:249-63.
22. Jansen RL, Slingerland R, Goei SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and Interferon-alpha in the treatment of patients with advanced non small cell lung cancer. J Immunother 1992;12:70-3.
23. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10-2:180-99.